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Efficacious typhoid vaccines for young children will significantly reduce the disease burden in developing world. 
The Vi polysaccharide based conjugate vaccines (Vi-rEPA) against Salmonella Typhi Vi positive strains has 
shown high efficacy but  may be ineffective against Vi negative S. Typhi. In this study, for the first time, we 
report the synthesis and evaluation of polysaccharide-protein conjugates of Vi negative S. Typhi as potential 
vaccine candidates. Four different conjugates were synthesized using recombinant exoprotein A of 
Pseudomonas aeruginosa (rEPA) and human serum albumin (HSA) as the carrier proteins, using either direct 
reductive amination or an intermediate linker molecule, adipic acid dihydrazide (ADH). Upon injection into mice, 
a significantly higher antibody titer was observed in mice injected with conjugate-1 (OSP-HSA) (P = 0.0001) and 
conjugate 2 (OSP-rEPA) (P = <0.0001) as compared to OSP alone. In contrast, the antibody titers elicited by 
conjugate 3 (OSPADH-HSA) and conjugate 4 (OSPADH-rEPA) were insignificant (P = 0.1684 and P = 0.3794, 
respectively). We conclude that reductive amination is the superior method to prepare the S. Typhi OSP 
glycoconjugate. Moreover, rEPA was a better carrier protein than HSA. Thus OSP-rEPA conjugate seems to be 
efficacious typhoid vaccines candidate, it may be evaluated further and recommended for the clinical trials. 
 
 
